Skip to main content
S&P 5007,670.99+1.04%DOW52,666.73+1.16%NASDAQ26,379.84+1.14%BTC$77,864.00+0.91%ETH$2,576.69+5.29%GOLD$4,402.60-0.11%OIL$99.96-2.46%
Smart Investors Daily
OK

NASDAQ · OKUR

OnKure Therapeutics, Inc.

Healthcare · Biotechnology

$3.27

Down-$0.18 (-5.50%)

Updated Sep 11, 2026, 5:04 PM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
44.44M
P/E ratio
-6.67
Dividend yield
0.00%
52-week range
$2.23 – $5.38
Volume
168.52K
Avg. volume
131.89K

Price performance

OKUR price history

1M range · 20 trading sessions · Daily adjusted prices

OKUR closed at $3.27 after 20 trading sessions, down 16.15% for the selected period.

Last close
$3.27
Period change
-16.15%
Period low
$3.27
Period high
$4.21
Daily close
View OHLC price history
OKUR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$3.36$3.42$3.24$3.27168.52K
Sep 9, 2026$3.38$3.4899$3.319$3.3880.09K
Sep 8, 2026$3.55$3.90$3.34$3.40115.01K
Sep 4, 2026$3.53$3.62$3.5075$3.58165.54K
Sep 3, 2026$3.56$3.62$3.52$3.56132.19K
Sep 2, 2026$3.54$3.665$3.41$3.54127.42K
Sep 1, 2026$3.62$3.70$3.4935$3.56193.56K
Aug 31, 2026$3.80$3.8999$3.54$3.63100.48K
Aug 28, 2026$3.83$4.02$3.67$3.79432.47K
Aug 27, 2026$3.77$3.86$3.77$3.8397.73K
Aug 26, 2026$3.86$4.0126$3.70$3.8080.36K
Aug 25, 2026$3.91$4.043$3.79$3.85116.23K
Aug 24, 2026$3.95$4.39$3.70$3.89421.07K
Aug 21, 2026$3.95$4.0728$3.90$3.9459.91K
Aug 20, 2026$4.04$4.043$3.78$3.93103.52K
Aug 19, 2026$4.29$4.42$4.07$4.08166.17K
Aug 18, 2026$4.11$4.27$3.99$4.21108.17K
Aug 17, 2026$3.97$4.28$3.85$4.11228.7K
Aug 14, 2026$3.90$4.13$3.83$3.99216.7K
Aug 13, 2026$3.95$4.09$3.86$3.9094.05K

Latest OKUR news

The latest Smart Investors Daily articles mentioning OKUR.

Stock researchCompany · Overview

OKUR research

Overview

Company profile and research snapshot.

Company profile

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$35.00
Implied upside
—
Analysts
—
OKUR recent ratings
DateFirmRatingTarget
Aug 14, 2026OppenheimerOutperform—
Jul 20, 2026HC Wainwright & Co.Buy—
Mar 16, 2026HC Wainwright & Co.Buy—
Aug 26, 2025HC Wainwright & Co.Buy—
Mar 18, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference

BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that senior management will participate in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference being held in New York on September 14 – 16, 2026. The OnKure management team will host one-on-one meetings during the conference. Interested investors should contact their Morgan

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By